← Issue №19/ week of Nov 8, 2026/ the whole section, in full

Pancreas/Biliary, in full.

All 8 Pancreas/Biliary papers in this issue, as full cards, ranked by clinical utility. The issue page carries the strongest few; this is the section, whole.

Sections this issue
Filter

All 8, in full

most clinically useful first · the 1 the issue led with is ruled in green
Pancreas/Biliary rct · n=757 · Nov 5, 2026 · NEJM · IF 84.5

Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.

New therapyacute pancreatitisbiomarkerepidemiology
Clinical takeawayPhase 3 evidence (SHASTA-3 and SHASTA-4, 757 adults) that lowering triglycerides with plozasiran 25 mg every 3 months lowers acute pancreatitis risk; check its approved indication before prescribing.
What it foundPlozasiran reduced acute pancreatitis risk to 1 per 100 patient-years vs 5 per 100 patient-years with placebo (rate ratio 0.22, P=0.008) and lowered triglycerides by 79-81% at 12 months. Adverse events occurred in 73% of patients in both plozasiran and placebo groups.
ContextTwo identically designed placebo-controlled trials; the pancreatitis result comes from a pooled analysis of adjudicated events. Adverse events occurred in 73% with plozasiran and with placebo.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Watts GF … SHASTA-3 and SHASTA-4 Study Groups · New England Journal of Medicine · IF 84.5 · PubMed ↗Permalink
Pancreas/Biliary retrospective · n=1,018 · Nov 5, 2026 · J Hepatobil Pancreat Sci · IF 3.8

Safety of Continuing Single-Agent Antithrombotic Therapy During Emergency Cholecystectomy for Acute Cholecystitis: An Overlap-Weighted Propensity Score Analysis With the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO).

New evidencecholedocholithiasisERCPbiliary stricture
Clinical takeawayWhen adequate antithrombotic washout is not feasible, these data support proceeding with emergency cholecystectomy for acute cholecystitis on single-agent therapy; the cohort was retrospective and the primary outcome was blood loss.
What it foundIntraoperative blood loss >100 mL occurred in 25.4% on continued single-agent antithrombotic therapy vs 27.3% without (RR 0.93, 95% CI 0.69-1.26), within the prespecified margin of 1.5; perioperative bleeding complications and stay did not differ.
ContextResults were consistent in sensitivity and drug-specific subgroup analyses, including direct oral anticoagulants (1,018 patients, seven institutions).
Emergingsuggested applicable standard· EASL (European Association for the Study of the Liver), "EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones," Journal of Hepatology 2016;65(1):146-181, 2016

… For acute cholecystitis, early laparoscopic cholecystectomy preferably within 72 h of admission should be performed by surgeons with adequate expertise (high quality; strong recommendation). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Abdominal ultrasound should be performed in a patient with a recent history of biliary pain (high quality evidence; strong recommendation); in case of strong clinical suspicion of gallbladder stones and negative abdominal ultrasound, EUS (or magnetic resonance imaging) may be performed (low quality; weak). Cholecystectomy is the preferred treatment for symptomatic gallbladder stones (moderate quality; strong recommendation), and laparoscopic cholecystectomy is the standard method, including for acute calculous cholecystitis (high quality; strong), although mini-laparotomy cholecystectomy (laparotomy <8 cm) is an equally acceptable alternative (high quality; strong). For uncomplicated biliary colic, cholecystectomy should be performed as early as possible (low quality; weak recommendation); EASL qualifies that cholecystectomy may not be necessary if biliary colic has not occurred within the last 5 years or after just one episode of colic (~50% chance of another colic within 1 year). For acute cholecystitis, early laparoscopic cholecystectomy preferably within 72 h of admission should be performed by surgeons with adequate expertise (high quality; strong recommendation). Antibiotics are NOT recommended at all times in mild acute cholecystitis, i.e. without cholangitis, bacteremia/sepsis, abscess or perforation (very low quality; weak recommendation). Biliary colic should be treated with NSAIDs, e.g. diclofenac 50-75 mg IM, ketoprofen 200 mg IV, or indomethacin 50 mg IV / 2 × 75 mg suppositories (moderate quality; weak), with spasmolytics and, for severe symptoms, opioids such as buprenorphine (low quality; strong). In severe acute cholecystitis or difficult biliary anatomy, subtotal cholecystectomy (laparoscopic or open) or percutaneous cholecystostomy followed by later cholecystectomy are options; percutaneous cholecystostomy is a treatment alternative in high-risk patients, but whether definitive cholecystectomy is still needed afterwards is explicitly unsolved (no RCTs) and cholecystectomy should be considered, since patients who improve after cholecystostomy may worsen during follow-up. In the elderly and those with high anaesthetic risk, cholecystectomy should be performed for gallstone complications (acute cholecystitis, gallstone pancreatitis, obstructive jaundice) as soon as general status allows (low quality; weak), and laparoscopic cholecystectomy should not be withheld on the basis of chronological age alone (very low quality; weak). Routine treatment is NOT recommended for asymptomatic gallbladder stones (very low quality; weak recommendation). Oral bile-acid litholysis, alone or with ESWL, is not recommended (moderate quality; strong). In patients with simultaneous gallbladder and bile duct stones, early laparoscopic cholecystectomy should be performed within 72 h after preoperative ERCP for choledocholithiasis (moderate quality; strong); same-day but separate ERCP and cholecystectomy are not recommended. Before elective cholecystectomy, abdominal ultrasound confirming stones is required (moderate quality; strong) and no other routine tests are necessary; liver biochemical tests in individually selected cases (very low quality; weak). Routine intraoperative cholangiography is not supported by current evidence.

EASL (European Association for the Study of the Liver), "EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones," Journal of Hepatology 2016;65(1):146-181, 2016 · reviewed 2026-07-23 ↗
Tadokoro T … Hiroshima Surgical Study Group of Clinical Oncology (HiSCO) · Journal of Hepato-Biliary-Pancreatic Sciences · IF 3.8 · PubMed ↗Permalink
Pancreas/Biliary retrospective · n=1,717 · Nov 1, 2026 · UEG Journal · IF 5.6

The Existence and Significance of Early Chronic Pancreatitis Within the AP-RAP-CP Sequence.

New evidenceacute pancreatitischronic pancreatitisepidemiology
Clinical takeawayNo clinical action yet: the registry describes which procedures were done, not whether they helped.
What it foundEndoscopic interventions shifted from prophylactic (71% in AP, 67% in RAP) to pancreatic duct-directed (42% in ECP, 77% in ACP) as disease progressed.
ContextRefines understanding of pancreatitis progression: ECP is a transitional phenotype between RAP and CP, with unique epidemiological and therapeutic characteristics.
Emergingsuggested applicable standard· American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720.

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Confirm chronic pancreatitis on CROSS-SECTIONAL IMAGING, CT for late calcific disease, MRI/MRCP (with secretin where available) for earlier ductal and parenchymal change, EUS an acceptable alternative; per ACG 2020, "Diagnosis is made usually on cross-sectional imaging, with modalities such as endoscopic ultrasonography and pancreatic function tests playing a secondary role". Fecal elastase does NOT confirm chronic pancreatitis: it is a test of exocrine FUNCTION and is the appropriate initial test for the exocrine pancreatic insufficiency (EPI) that chronic pancreatitis causes, a consequence of the disease, not the diagnosis of it. A normal fecal elastase does not exclude chronic pancreatitis and a low one does not establish it. Per AGA 2023, fecal elastase must be run on a semi-solid or solid stool specimen; below 100 mcg/g is good evidence of EPI and 100-200 mcg/g is indeterminate (below 200 mcg/g is the cutoff commonly used to screen). Then manage with smoking and alcohol cessation, PERT for exocrine insufficiency titrated to symptoms, fat-soluble vitamin and bone surveillance, and individualized type 3c diabetes control, considering insulin early in patients with marked hyperglycemia or symptoms of insulin deficiency. Treat pain with a stepwise ladder from scheduled acetaminophen and neuromodulators to EUS-guided celiac plexus block and endoscopic/surgical intervention, referring early for surgery per ESCAPE 2020 in candidates with main pancreatic duct obstruction. Screen for PDAC per lifetime risk and pursue etiologic workup via TIGAR-O v2, including genetic testing and autoimmune pancreatitis evaluation.

American College of Gastroenterology, 'ACG Clinical Guideline: Chronic Pancreatitis' (Gardner TB et al., Am J Gastroenterol 2020;115(3):322-339). DOI 10.14309/ajg.0000000000000535, PMID 32022720. · reviewed 2026-07-21 ↗
Venglovecz V … Hungarian Pancreatic Study Group · United European Gastroenterology Journal · IF 5.6 · PubMed ↗Permalink
Pancreas/Biliary retrospective · n=1,382 · Nov 4, 2026 · J Gastroenterology · IF 5.7

From trial efficacy to real-world effectiveness: evaluating the generalizability of cisplatin-gemcitabine-durvalumab in advanced biliary tract cancers.

New evidencecholangiocarcinomabiliary stricturepancreatic cancer
Clinical takeawayReal-world outcomes support CGD as the first-line standard in advanced biliary tract cancer, including for patients outside TOPAZ-1 eligibility, whose survival was similar to the trial arm.
What it foundOverall survival in 1,382 real-world patients from 55 centres was longer than in the reconstructed TOPAZ-1 CGD arm (HR 0.83, p=0.012; calibrated HR 0.84); trial-eligible patients did better than the trial population (HR 0.76) and trial-ineligible patients similarly (HR 0.98).
ContextRetrospective comparison against reconstructed trial data; the larger differences for ECOG PS 0 and locally advanced disease are exploratory.
Reinforcessuggested applicable standard· NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Stage cholangiocarcinoma with multiphasic MRI/MRCP plus CT chest/abdomen/pelvis, obtain tissue via ERCP brush cytology with FISH, cholangioscopy-directed biopsy, or EUS-FNA (avoiding primary perihilar tumor sampling if liver transplant is being considered due to theoretical seeding risk), and manage through a multidisciplinary tumor board with treatment stratified by tumor location: resect (anatomic hepatectomy for intrahepatic, hemihepatectomy with bile duct resection for perihilar, Whipple for distal) with adjuvant capecitabine (category 1, per BILCAP) when resectable. For unresectable or metastatic disease, first-line systemic therapy is gemcitabine plus cisplatin combined with a PD-L1/PD-1 checkpoint inhibitor, either durvalumab (TOPAZ-1) or pembrolizumab (KEYNOTE-966), both listed as category 1 preferred options by NCCN; comprehensive molecular/genomic profiling is recommended for all unresectable/metastatic candidates for systemic therapy to identify actionable targets (e.g., FGFR2 fusions, IDH1 mutations, HER2 amplification) for later-line therapy. Selected unresectable early-stage perihilar tumors may undergo neoadjuvant chemoradiation and liver transplant per the Mayo Clinic protocol at experienced centers, and jaundice or cholangitis is managed with biliary drainage (ERCP preferred over PTC).

NCCN Biliary Tract Cancers V2.2025 (V1.2026 in circulation) / AASLD 2023 Practice Guidance on PSC and Cholangiocarcinoma · reviewed 2026-07-21 ↗
Camera S … Casadei-Gardini A · Journal of Gastroenterology · IF 5.7 · PubMed ↗Permalink
Pancreas/Biliary rct · n=100 · Nov 2, 2026 · Pancreatology · IF 3.0

Transdermal buprenorphine versus intravenous tramadol for pain management in acute pancreatitis: A prospective randomized controlled trial.

New evidenceacute pancreatitis
Clinical takeawayNo change yet: the primary endpoint was missed, and the authors call the Day 2 rescue-analgesia benefit hypothesis-generating.
What it foundTransdermal buprenorphine (10 μg/h) reduced rescue analgesia need on Day 2 (14% vs 34%, RR 0.41, NNT 5) and Days 2-3 (14% vs 36%, RR 0.39) compared to intravenous tramadol (100 mg every 8 h) in adults with acute pancreatitis and baseline VAS score ≥7.
ContextThis trial did not meet its primary endpoint but suggests transdermal buprenorphine may reduce rescue analgesia needs from Day 2 without increasing adverse events compared to intravenous tramadol in adults with acute pancreatitis and baseline VAS score ≥7.
Emergingsuggested applicable standard· American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437

Diagnose acute pancreatitis (AP) by the Atlanta criteria (2 of 3: characteristic epigastric/LUQ pain, lipase or amylase >3x ULN [lipase preferred for specificity/duration], or characteristic imaging). …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnose acute pancreatitis (AP) by the Atlanta criteria (2 of 3: characteristic epigastric/LUQ pain, lipase or amylase >3x ULN [lipase preferred for specificity/duration], or characteristic imaging). ACG 2024 stratifies severity risk using SIRS on admission plus bedside risk factors, rising/elevated BUN, rising/elevated hematocrit (>44), obesity (BMI>30), extrapancreatic fluid collections/pleural effusion/infiltrates, altered mental status, and older age/comorbidities, rather than mandating a formal BISAP or APACHE II composite score. Give moderately aggressive lactated Ringer's, most important in the first 6-12 hours, reassessing volume status/BUN/HCT at 6 hours (further aggressive hydration has little added benefit after 24-48h). Start oral low-fat solid food within 24-48h as tolerated in mild disease; if enteral feeding is needed for moderately severe/severe disease, prefer nasogastric over nasojejunal with small-peptide/medium-chain-triglyceride formula and continuous (not bolus/cyclic) feeding; avoid parenteral nutrition if possible. Do not give prophylactic antibiotics, even in severe disease or sterile necrosis; reserve antibiotics for suspected infected necrosis (typically arising 10-14 days in), and choose agents that penetrate pancreatic necrosis while together covering both gut-derived gram-negative enterics and anaerobes, a carbapenem supplies this as monotherapy, whereas a fluoroquinolone or a third-or-higher-generation cephalosporin must be combined with metronidazole; metronidazole alone (anaerobic cover only), or a cephalosporin or a quinolone alone, does not adequately treat infected necrosis. Perform cholecystectomy preferably before discharge for mild acute biliary pancreatitis, and after a second unexplained AP episode even without identified gallstones; reserve ERCP within 24h for AP complicated by cholangitis, with rectal indomethacin +/- pancreatic duct stent and periprocedural hydration to reduce post-ERCP pancreatitis risk. Check triglycerides when gallstones/alcohol are absent (>1000 mg/dL supports a hypertriglyceridemia etiology). For stable pancreatic necrosis, defer surgical, radiological, or endoscopic intervention 4-6 weeks to allow walling-off (step-up approach).

American College of Gastroenterology, "American College of Gastroenterology Guidelines: Management of Acute Pancreatitis" (Tenner S, Vege SS, Sheth SG, et al.), Am J Gastroenterol 2024;119(3):419-437 · reviewed 2026-07-20 ↗
Singla SP … Acharya SK · Pancreatology : Official Journal of the International Association of Pancreatology (IAP) .. [et Al.] · IF 3.0 · PubMed ↗Permalink
Pancreas/Biliary prospective cohort · n=64 · Nov 1, 2026 · Dig Endosc · IF 5.2

Segment-Specific Occlusion of Retrieved Plastic Biliary Stents: Direct Quantification and Microbial and Material Determinants.

New evidencebiliary strictureERCPmicrobiomebiomarker
Clinical takeawayNo clinical action is recommended yet; this observational study highlights segment-specific occlusion patterns and associated factors, which may inform future stent design and management strategies.
What it foundProximal stent segment occlusion was 35.5% vs. 25.8% central and 25.0% distal (p < 0.05), with age > 65, Enterococcus-positive bile culture, and probiotic use independently increasing occlusion. Stent brand was also associated with occlusion, but specifics are in the source.
ContextConfirms segment-specific occlusion patterns in plastic biliary stents and identifies modifiable risk factors, refining current understanding of stent failure.
Measured against the standard of care· ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis)

… Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. … Use plastic stents when the drainage strategy is undefined or the centre is not expert. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnosis is unchanged and still follows the separate ESGE diagnostic guideline (Endoscopy 2025;57:166-185). Start with MRI/MRCP plus laboratory tests, read CA19-9 only after decompression, and check IgG4 when IgG4-related sclerosing cholangitis is suspected. For distal extrahepatic strictures with no pancreatic mass, do combined same-session EUS-guided tissue acquisition plus ERCP brushing and biopsy. For perihilar strictures, sample by ERCP first and move to cholangioscopy-guided biopsy if the result is indeterminate. Do not place an uncovered SEMS (USEMS) until malignancy is confirmed. Management now follows the 2026 ESGE biliary stricture management guideline, which replaces the 2018 stenting guideline and brings it into line with the 2022 therapeutic EUS guideline. Benign: post-cholecystectomy strictures get temporary multiple plastic stents (MPSs), exchanged every 3-4 months with as many stents as possible, for about 12 months. A fully covered SEMS (FCSEMS) is an option only if the stricture is more than 2 cm below the hepatic confluence or the patient will not comply with repeated ERCPs. Anastomotic strictures after liver transplant get MPSs, or a temporary FCSEMS if more than 2 cm below the confluence. Nonanastomotic post-transplant strictures that can be treated endoscopically get MPSs plus balloon dilation if needed. Chronic pancreatitis strictures get a temporary 8-10 mm FCSEMS for 6-12 months. High-grade PSC strictures get balloon dilation alone, with no stent, because stenting adds no benefit and may add adverse events. Endotherapy is indicated for a benign stricture with liver tests raised for more than 1 month and/or cholangitis. Malignant distal: drain before surgery only selectively (cholangitis, severe jaundice or pruritus, delayed surgery). When drainage is needed before surgery or neoadjuvant therapy, or for palliation, place a 10-mm SEMS endoscopically. Endoscopic drainage is preferred over surgery or PTBD for inoperable obstruction. Malignant hilar: manage in high-volume centres with a hepatobiliary multidisciplinary team (MDT). ERCP is preferred over PTBD for preoperative drainage. Palliate Bismuth I-II with ERCP. For Bismuth III-IV, ERCP or ERCP combined with EUS-guided drainage (EUS-BD) is preferred over primary PTBD, with PTBD as a complement if needed. For proven Bismuth II-IV, aim to drain more than 50%, ideally 70% or more, of the viable nonatrophic liver volume using several routes as needed. Use plastic stents when the drainage strategy is undefined or the centre is not expert. USEMS are for expert centres when the diagnosis is proven, the tumour is unresectable, and complete drainage is predicted. After failed or unfeasible ERCP, EUS-BD is recommended over PTBD. Use hepaticogastrostomy (EUS-HGS) if there is a duodenal stricture, and EUS-HGS or choledochoduodenostomy (EUS-CDS) if there is not. PTBD is used if EUS-BD fails. In surgically altered anatomy, benign disease gets enteroscopy-assisted ERCP first; malignant disease gets enteroscopy-assisted ERCP or EUS-BD. Give antibiotics before ERCP in selected cases: predicted incomplete drainage, hilar strictures, immunocompromised patients, PSC, cholangioscopy. This follows the ESGE ERCP-adverse-events guideline. Etiology-specific care (Strasberg injuries, IgG4-SC, Mirizzi, choledochal cysts) is unchanged.

ESGE 2026 (biliary stricture management; replaces ESGE 2018 stenting guideline) / ESGE 2025 (biliary stricture diagnosis) · reviewed 2026-10-11 ↗
Matsumi A … Otsuka M · Digestive Endoscopy : Official Journal of the Japan Gastroenterological Endoscopy Society · IF 5.2 · PubMed ↗Permalink
Pancreas/Biliary retrospective · n=641 · Nov 5, 2026 · J Hepatobil Pancreat Sci · IF 3.8

Conditional Survival of Gallbladder Cancer After Curative-Intent Surgery: Impact of Disease Stage, Surgical Extent, and Adjuvant Therapy.

New evidencecholangiocarcinoma
Clinical takeawayUse conditional survival to update prognosis for patients who have survived years after resection; the better course with extended cholecystectomy and adjuvant therapy in stage II-III is a retrospective association.
What it foundFive-year conditional overall survival (COS) increased from 69.4% at baseline to 74.0% among patients surviving 5 years, with Stage III patients showing the largest improvement (45.9%-69.4%).
ContextThis study refines prognostication in gallbladder cancer by introducing conditional survival estimates, which evolve over time, unlike conventional static survival estimates. The findings apply to patients who have undergone curative-intent resection, with specific attention to Stage II-III disease.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Kim HS … Kim H · Journal of Hepato-Biliary-Pancreatic Sciences · IF 3.8 · PubMed ↗Permalink
Pancreas/Biliary retrospective · n=13,574,975 · Nov 3, 2026 · J Clin Gastro · IF 2.9

Acid Suppression and Pancreatitis: Are PCABs Safer Than PPIs? A Global Database Analysis.

Practice-changingacute pancreatitisepidemiology
Clinical takeawayNo clinical action yet: pancreatitis risk did not differ significantly, and the lower odds of respiratory failure, renal failure, sepsis and death with PCABs come from a retrospective database cohort.
What it foundPCAB use was not associated with a statistically significant difference in new-onset AP compared with PPI (OR: 0.624; P=0.24), with AP incidence of 0.65% vs 0.96% within 90 days.
ContextTriNetX cohort of 77,841 PCAB and 13.5 million PPI users, propensity matched.
No standard claimed for this paper

Every paper is compared to the standard governing its question. This one is not: either no standard in the corpus matches it, or the comparison did not hold up on review and was withdrawn rather than published unverified. Both are logged.

Sunkesula V … Waghray N · Journal of Clinical Gastroenterology · IF 2.9 · PubMed ↗Permalink
← Back to issue №19 Every section of this issue is one click away, at the top of this page. Follow Pancreas/Biliary by RSS